Pages that link to "Q74195334"
Jump to navigation
Jump to search
The following pages link to Evaluation of antiandrogen therapy in unresectable hepatocellular carcinoma: results of a European Organization for Research and Treatment of Cancer multicentric double-blind trial (Q74195334):
Displaying 35 items.
- Systemic therapy of hepatocellular carcinoma: current status and future perspectives (Q26865844) (← links)
- The Expression of Estrogen Receptors in Hepatocellular Carcinoma in Korean Patients (Q27488435) (← links)
- Hepatocellular carcinoma (Q29615841) (← links)
- Management of hepatocellular carcinoma (Q29616230) (← links)
- Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver (Q29616866) (← links)
- Nonalcoholic steatohepatitis-related hepatocellular carcinoma: is there a role for the androgen receptor pathway? (Q30234736) (← links)
- Hepatocellular carcinoma in central Sydney:a 10-year review of patients seen in a medical oncology department (Q34511954) (← links)
- Hepatocellular carcinoma--cause, treatment and metastasis (Q34512068) (← links)
- Chemotherapy and Other Systemic Therapies for Hepatocellular Carcinoma and Liver Metastases (Q34563336) (← links)
- Sex hormones and liver cancer (Q34772485) (← links)
- Are there indications for chemotherapy in hepatocellular carcinoma? (Q35123001) (← links)
- Long acting octreotide in the treatment of advanced hepatocellular cancer and overexpression of somatostatin receptors: randomized placebo-controlled trial (Q35621231) (← links)
- Treatment of hepatocarcinoma (Q35739061) (← links)
- Systemic treatment and liver transplantation for hepatocellular carcinoma: two ends of the therapeutic spectrum (Q35824978) (← links)
- Systemic treatment and targeted therapy in patients with advanced hepatocellular carcinoma (Q35913461) (← links)
- Haematogenous abdominal wall metastasis of differentiated, alpha-fetoprotein-negative hepatocellular carcinoma after previous antiandrogen therapy within a site of lipoma manifestation since childhood (Q36127730) (← links)
- New aspects of diagnosis and therapy of hepatocellular carcinoma. (Q36519032) (← links)
- A phase II study of the vitamin D analogue Seocalcitol in patients with inoperable hepatocellular carcinoma (Q36670965) (← links)
- The androgen receptor as an emerging target in hepatocellular carcinoma (Q37031766) (← links)
- Is human hepatocellular carcinoma a hormone-responsive tumor? (Q37113547) (← links)
- Update on new approaches in the management of hepatocellular carcinoma (Q37356150) (← links)
- Androgen/androgen receptor axis maintains and promotes cancer cell stemness through direct activation of Nanog transcription in hepatocellular carcinoma (Q37392841) (← links)
- Males develop faster and more severe hepatocellular carcinoma than females in krasV12 transgenic zebrafish (Q37602180) (← links)
- Androgen Receptor Could Be a Potential Therapeutic Target in Patients with Advanced Hepatocellular Carcinoma (Q38802507) (← links)
- A meta-analysis of survival rates of untreated patients in randomized clinical trials of hepatocellular carcinoma (Q39905453) (← links)
- Therapy of experimental hepatic cancers with cytotoxic peptide analogs targeted to receptors for luteinizing hormone-releasing hormone, somatostatin or bombesin (Q39985777) (← links)
- Apoptotic and anti-proliferative effects of 17beta-estradiol and 17beta-estradiol-like compounds in the Hep3B cell line (Q40241047) (← links)
- Systemic Chemotherapy for Advanced Hepatocellular Carcinoma: Past, Present, and Future (Q42343451) (← links)
- Altered androgen metabolism eventually leads hepatocellular carcinoma to an impaired hormone responsiveness (Q44088366) (← links)
- Hepatocellular carcinoma (Q57696098) (← links)
- [Palliative treatment of hepatocellular carcinoma] (Q80052042) (← links)
- Non-surgical treatment of hepatocellular carcinoma (Q80850384) (← links)
- Management of hepatocellular carcinoma (Q83816502) (← links)
- RefDNN: a reference drug based neural network for more accurate prediction of anticancer drug resistance (Q89555969) (← links)
- Olaparib and enzalutamide synergistically suppress HCC progression via the AR-mediated miR-146a-5p/BRCA1 signaling (Q90063180) (← links)